According to a report by Grand View Research, Inc.; the
global cell
line development market is projected to reach a valuation of around USD
6.24 billion by 2022. Rising demand for monoclonal antibodies and availability
of advanced techniques to develop new cell lines can propel the market during
the forecast period (2012 to2022).
Additionally, factors such as growing adoption of
regenerative medicine, favorable government efforts and growing expenditure for
biotechnology industry can further impel market expansion. Improving healthcare
infrastructure and economic development can have positive impact on the market
over the forecast period. Apart from that, growing occurrence of autoimmune
diseases and cancer can propel the market for cell line development in near
future.
Flourishing biopharmaceutical industry is expected to
increase the need for cell line development technique in the coming years.
Cells can be used as an expansion host for the production of recombinant
monoclonal antibodies in various biopharma companies. Growing production of
biosimilars owing to patent expiration of branded biologics as well as recombinant
proteins is also expected to boost the cell line development market over the
forecast period.
Moreover, high prevalence of chronic diseases has
increased the need for effective treatment solutions. This is expected to fuel
the demand for drugs, vaccines, biosimilars, and therapeutic proteins. The
vaccines developed using animal cells are used to treat many conditions such as
rotavirus, smallpox, polio, Japanese encephalitis, hepatitis A, varicella, rabies,
zoster, and rubella. This is one of the primary drivers for the global market.
Furthermore, ongoing research and development for
stable and authentic cell lines and development of technologically advance
procedures like micro bioreactor and single use bioreactor for large sized bioproduction
can provide lucrative growth opportunities for the market. Rise in biotechnology
based applications such as cell culture, gene therapy, and drug discovery can
provide significant traction for the global market in near future.
Browse full research report on Cell Line Development Market:
www.grandviewresearch.com/industry-analysis/cell-line-development-market
The worldwide cell line development market can be
segmented on the basis of product, source, type, and region. Based on type, the
market can be fragmented into reagents and media, accessories and consumables,
and equipment. As per source, the market can be categorized into mammalian and
non-mammalian. Based on type, the market can be classified into hybridomas, recombinant
cell lines, continuous cell line, and primary cell lines.
Geographically, the market can be divided into Europe,North
America, Asia Pacific, Latin America, Middle East & Africa. In 2014, North
America held the largest revenue share owing to high adoption of cell culture
techniques, availability of developed infrastructure, supportive government
initiatives and high healthcare expenditure. In addition, increasing awareness
regarding monoclonal antibodies application in the treatment of cancer and
development of innovative procedures for bioproduction are some of the significant
factors influencing the regional market. In addition, existence of research
organizations like Sigma-Aldrich Corporation, American Type Culture Collection
(ATCC), and others that are providing high-quality biologics services can also be
attributed towards the regional market growth.
Asia Pacific is likely to exhibit lucrative growth during
the forecast period due to growing investment in healthcare infrastructure by government
and private sectors. Increasing number of contract research organizations (CROs)
providing pertinent services is also anticipated to impel regional market over
the forecast period. In addition, increasing research and development (R&D)
efforts for the establishment of stable cell lines and growing biologics
production can create positive outlook for the market.
Browse more reports of this category
by Grand View Research: www.grandviewresearch.com/industry/biotechnology
The biotechnology industry is expected to grow swiftly
in emerging countries over the forecast period. This growth can be accredited
to improving healthcare infrastructure and rise in public healthcare programs.
For instance, in India, several organizations such as the Department of
Biotechnology (DBT), Department of Scientific & Industrial Research (DSIR),
and Department of Science and Technology (DST) are regulating the production. These
organizations offer guidelines associated with raising funds, making or
transferring technology, and creating manpower for the production. Such efforts
can boost the market in the region.
Some of the leading companies operating in the cell
line development market include Wuxi AppTec Inc.; Corning Inc.; Thermo Fisher
Scientific Inc.; and Sigma-Aldrich Corporation. The market is extremely competitive
and is expected to witness strategic initiatives like mergers and acquisitions
(M&A), partnership agreements, patent registration, and licensing in near
future.
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment